

Stock Information:

Symbol:	OTC:GSAC
Price:	\$0.011
Shares Outstanding:	391M
Market Cap.:	\$4.3M



GelStat Corporation (OTC: GSAC) is a publicly-traded holding company. Through its wholly owned subsidiary Mastix Medica, develops, manufactures and brands niche healthcare products such as tableted chewing gum, chewable tablets and lozenges. Mastix is one of very few companies in the world (and the only one in the U.S.) that has the ability to make tableted chewing gum products at room temperature versus the traditional high heat process which degrades the active ingredients and reduces their efficacy. Most importantly, Mastix is the only company that manufactures its own powdered gum base using its proprietary process. This allows Mastix the flexibility to create custom formulations that other companies cannot and do not offer. Furthermore, it has a patent pending process for its unique gum manufacturing process that includes incorporating hemp oil into chewing gum, lozenges and chewable tablets.

Manufacturing Operations

Mastix Medica tableted products are available in a variety of dosage forms for a diverse customer base, and serve domestic and international markets. Mastix contract manufactures and private labels tableted chewing gum, chewable tablets, lozenges, mints and candy for its customers who include national brand leaders, small niche marketers, the U.S. Military, and for export. The product categories currently addressed include dietary supplements, functional chewing gum, functional foods and confectionery, medicated confectionery and candy. "Functional" here refers to the delivery of active ingredients of benefit to the consumer beyond taste and general nutrition. With Mastix's innovative and capable staff, new formulations can be offered to satisfy an expanding list of customer inquiries for such tableted products.

Mastix Medica produces products in its 28,000 square foot facility just north of Baltimore in Hunt Valley, Maryland. The products are manufactured in a Kosher certified (Star-K), allergen-free and quality-driven FDA GMP-compliant manufacturing environment.


Competitive Advantages

Mastix Medica specializes in developing products that provide faster absorption of active ingredients in tableted chewing gum and lozenge dosage forms. The functional gum is formed into a tableted composition using unique proprietary know-how, adding active ingredients to a powdered gum base and then using direct compression in a tablet press, thus making a gum product that has content uniformity of actives from piece to piece. Unlike the

few other companies that make tableted gum, Mastix is the only company that manufactures its own powdered gum base using its proprietary process. This allows Mastix the flexibility to create custom formulations that other companies cannot and do not offer. In comparison to Mastix, conventional gum manufacturers use a high temperature extruded process that kills many active ingredients, which results in a sub-potent, less efficacious final product. Mastix' gum products are manufactured under FDA GMP regulations at room temperature allowing the concentration of the added active ingredients to be lab tested and fully effective in the final product.

Mastix Medica offers chewing gum products, lozenges and chewable tablets with hemp oil which is rich in cannabidiol (CBD). Mastix is the only chewing gum manufacturer that can incorporate an active ingredient like hemp oil into a piece of chewing gum. We have a patent pending for this intellectual property. The hemp oil used by Mastix meets all US GMP, FDA and DEA regulations (very low THC content -- less than 0.3%).

Select Products



Business Model

The company's business model revolves around leveraging its manufacturing expertise, competitive advantages and intellectual property to establish multiple revenue streams and liquidity events.

This model includes:

- Formulating and contract manufacturing custom products for customers.
- Formulating, validating the effectiveness, applying for patents and manufacturing private label products for customers looking for unique turn-key opportunities.
- Incubating proprietary products using a proven hybrid direct-response/select retail model and positioning them for sale to large consumer products companies.
- Licensing our proprietary manufacturing process for upfront and ongoing royalty fees.

Leadership

Robert (Bob) Estey, Chief Operation Officer

The founder of Mastix Medica, Mr. Estey has led companies through successful turnaround and start-up situations. In these situations, Mr. Estey had CFO and operational responsibilities at ANI Pharmaceuticals, Xanodyne Pharmaceuticals, Alpharma's U.S. Generic Pharmaceutical Division and Florida Tile Industries.

Gerald Kieft, Chief Financial Officer & Director

Mr. Kieft was the interim CEO for GelStat Corporation since June of 2008 as he led its turnaround. In June of 2013 he was appointed as the Company's CFO. Throughout his career in the finance industry, Mr. Kieft has helped emerging growth companies raise capital and develop growth strategies.

Roger Cady, MD, Chief Medical Advisor

Dr. Cady is the founder of Headache Care Center, Clinvest, and Primary Care Education. He is a graduate of the Mayo Medical

School, and is Board Certified by the American Board of Family Practice. His board certification in Headache Medicine was awarded by the United Council for Neurologic Subspecialties, and he holds a Certificate of Added Qualification through the National Board of Certification in Headache Management. He is a member of multiple medical associations, including the American Medical Association, the National Headache Foundation, the American Headache Society, the American Academy of Pain Management, and the American Academy of Family Physicians.



Investment Considerations

GelStat Corporation and its wholly owned subsidiary Mastix Medica have significant competitive advantages in functional gum and lozenge niches as well as with CBD infused products. Collectively, the revenue potential from these niches could be in the hundreds of millions.

The current manufacturing operations have the capacity of generating \$20 million to \$30 million in revenue and it turns cash flow positive with revenue between \$650,000 and \$750,000 per quarter. This is a very obtainable goal given that the company was able to generate \$750,000 in revenue and was slightly cash flow positive in the 4th quarter of 2014.

GelStat provides risk tolerant investors with a startup valuation in a company that has existing operations and proven manufacturing capabilities, public company liquidity and a stake in the explosive CBD market.

Investor Contact:

Gerald Kieft
Chief Financial Officer
410-316-1082 (tel)
gkieft@GelStat.com
www.gelstat.com

Disclaimer—This Fact Sheet on GelStat Corporation ("GelStat" or the "Company"), is provided to you without charge as a convenience and for your information only. Whenever we use the term "content", we are referring to any materials, documents, images, graphics, logos, design, audio, video and any other information provided within this document. By merely providing access to this document, we do not warrant or represent, and you should not assume, that the content in this document includes all material information pertaining to GelStat or that such content represents the most current and up-to-date material information that is publicly available with respect to the Company. Information included was current at the time of inclusion, but may be superseded by subsequent disclosures. Whenever we use the term "material information", we mean information relating to the business, operations or securities of GelStat that would reasonably be expected to significantly affect the value of the Company or the common shares of GelStat.